Hiroki Tawaratsumida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroki Tawaratsumida has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Tominaga
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Noboru Taniguchi
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Shingo Maeda
Department of Bone and Joint Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Yusuke Masuda
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
3 shared publications - Hideo Otsubo
Center for Rheumatic Diseases, Japanese Red Cross Kagoshima Hospital, Kagoshima 891-0133, Japan
2 shared publications - Kento Shimanoe
Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4) , 100884
Inhibition of BMP–Smad1/5 signaling with DMH1 attenuates joint degeneration in a rat model of cuff tear arthropathy
- 6 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4) , 100884
Open AccessInhibition of BMP–Smad1/5 signaling with DMH1 attenuates joint degeneration in a rat model of cuff tear arthropathy
- Open Access
- 2 October 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (10) , 1183-1195
Anti-RANKL antibody treatment mitigates subchondral bone loss and cartilage degeneration without affecting synovial inflammation in a mouse model of rotator cuff tear arthropathy
Aims: Enhanced osteoclast activity in subchondral bone is implicated in osteoarthritis (OA) progression, but the contribution of osteoclasts versus synovial inflammation in cuff tear arthropathy (CTA) remains unclear. This study investigated whether inhibition of osteoclasts using an anti-receptor activator of nuclear factor κB ligand (RANKL) antibody can suppress joint degeneration in a mouse CTA model without affecting synovial inflammation. Methods: A modified CTA (mCTA) model was established in mice by resecting the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon in the right shoulder of C57BL/6J mice. Mice were assigned to four groups: sham or mCTA, each treated with phosphate-buffered saline or anti-RANKL antibody (5 mg/kg subcutaneously every two weeks). Four weeks post-surgery, histological analyses of the humeral head were performed using the Murine Shoulder Arthritis Score (MSAS), immunohistochemistry for osteoclasts, osteoblasts, RANKL/osteoprotegerin (OPG), inflammatory cytokines, and catabolic enzymes, and quantification of synovial M1 macrophages. Subchondral bone volume (BV) was assessed via the bone volume/tissue volume ratio. Results: The mouse mCTA model reproduced clinically relevant CTA phenotypes, including cartilage degeneration, subchondral bone loss, and joint surface collapse, within four weeks. RANKL expression and osteoclast surface increased in the superior and middle zones, while osteoblasts decreased. Synovial RANKL expression was low and unchanged after mCTA surgery. Anti-RANKL antibody administration significantly suppressed osteoclast surface and preserved subchondral BV, leading to attenuation of cartilage degeneration and reduced expression of inflammatory cytokines and catabolic enzymes in cartilage and subchondral bone. The synovitis score, synovial M1 macrophages, and inflammatory factors were unaffected, indicating that suppression of osteoclasts was sufficient to mitigate joint degeneration. Conclusion: Inhibition of subchondral osteoclasts via anti-RANKL antibody reduces CTA-associated cartilage and bone degeneration without altering synovitis. These findings suggest that targeting osteoclasts may represent a promising disease-modifying strategy for CTA, and targeting RANKL with denosumab may prevent or slow shoulder OA progression. Cite this article: Bone Joint Res 2026;15(10):1183–1195.
- 2 October 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (10) , 1183-1195
Open AccessAnti-RANKL antibody treatment mitigates subchondral bone loss and cartilage degeneration without affecting synovial inflammation in a mouse model of rotator cuff tear arthropathy
Aims: Enhanced osteoclast activity in subchondral bone is implicated in osteoarthritis (OA) progression, but the contribution of osteoclasts versus synovial inflammation in cuff tear arthropathy (CTA) remains unclear. This study investigated whether inhibition of osteoclasts using an anti-receptor activator of nuclear factor κB ligand (RANKL) antibody can suppress joint degeneration in a mouse CTA model without affecting synovial inflammation. Methods: A modified CTA (mCTA) model was established in mice by resecting the supraspinatus and infraspinatus tendons, the superior joint capsule, and the long head of the biceps tendon in the right shoulder of C57BL/6J mice. Mice were assigned to four groups: sham or mCTA, each treated with phosphate-buffered saline or anti-RANKL antibody (5 mg/kg subcutaneously every two weeks). Four weeks post-surgery, histological analyses of the humeral head were performed using the Murine Shoulder Arthritis Score (MSAS), immunohistochemistry for osteoclasts, osteoblasts, RANKL/osteoprotegerin (OPG), inflammatory cytokines, and catabolic enzymes, and quantification of synovial M1 macrophages. Subchondral bone volume (BV) was assessed via the bone volume/tissue volume ratio. Results: The mouse mCTA model reproduced clinically relevant CTA phenotypes, including cartilage degeneration, subchondral bone loss, and joint surface collapse, within four weeks. RANKL expression and osteoclast surface increased in the superior and middle zones, while osteoblasts decreased. Synovial RANKL expression was low and unchanged after mCTA surgery. Anti-RANKL antibody administration significantly suppressed osteoclast surface and preserved subchondral BV, leading to attenuation of cartilage degeneration and reduced expression of inflammatory cytokines and catabolic enzymes in cartilage and subchondral bone. The synovitis score, synovial M1 macrophages, and inflammatory factors were unaffected, indicating that suppression of osteoclasts was sufficient to mitigate joint degeneration. Conclusion: Inhibition of subchondral osteoclasts via anti-RANKL antibody reduces CTA-associated cartilage and bone degeneration without altering synovitis. These findings suggest that targeting osteoclasts may represent a promising disease-modifying strategy for CTA, and targeting RANKL with denosumab may prevent or slow shoulder OA progression. Cite this article: Bone Joint Res 2026;15(10):1183–1195.
- Open Access
- 15 August 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (1) , 101-115
Zoledronate alleviates subchondral bone collapse and articular cartilage degeneration in a rat model of rotator cuff tear arthropathy
- 15 August 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (1) , 101-115
Open AccessZoledronate alleviates subchondral bone collapse and articular cartilage degeneration in a rat model of rotator cuff tear arthropathy
- Open Access
- 21 December 2017
- Published by Springer Nature in BMC Research Notes
- Vol. 10 (1) , 765
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients’ variables to identify risk factors for least significant reduction of bone mineral density. Least significant reduction of lumbar spine bone mineral density (≤ − 2.4%) was seen in 13.1% of patients. Least significant reduction of femoral neck bone mineral density (≤ − 1.9%) was seen in 34.0% of patients. Multiple logistic regression analysis showed that a risk factor for least significant reduction of the lumbar spine was high-dose methylprednisolone use. Multiple regression analysis showed that a risk factor for least significant reduction of the femoral neck was short disease duration. Our findings showed that a risk factor for femoral neck bone mineral density reduction was a short disease duration. These findings suggest that rheumatoid arthritis patients receiving treatment with biological disease-modifying anti-rheumatic drugs may benefit from earlier osteoporosis treatments to prevent femoral neck bone loss.
- 21 December 2017
- Published by Springer Nature in BMC Research Notes
- Vol. 10 (1) , 765
Open AccessRisk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Osteoporosis is a complication of rheumatoid arthritis. We examined the risk factors for bone loss in rheumatoid arthritis patients receiving biological disease-modifying anti-rheumatic drugs. Lumbar spine and femoral neck bone mineral density was measured at two time points in 153 patients with rheumatoid arthritis managed with biological disease-modifying anti-rheumatic drugs. We examined patients’ variables to identify risk factors for least significant reduction of bone mineral density. Least significant reduction of lumbar spine bone mineral density (≤ − 2.4%) was seen in 13.1% of patients. Least significant reduction of femoral neck bone mineral density (≤ − 1.9%) was seen in 34.0% of patients. Multiple logistic regression analysis showed that a risk factor for least significant reduction of the lumbar spine was high-dose methylprednisolone use. Multiple regression analysis showed that a risk factor for least significant reduction of the femoral neck was short disease duration. Our findings showed that a risk factor for femoral neck bone mineral density reduction was a short disease duration. These findings suggest that rheumatoid arthritis patients receiving treatment with biological disease-modifying anti-rheumatic drugs may benefit from earlier osteoporosis treatments to prevent femoral neck bone loss.
- Open Access
- 30 September 2015
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 16 (1) , 269
Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
Osteoporosis is a complication of rheumatoid arthritis (RA). We identified risk factors for osteoporosis during treatment with biologics. Femoral neck bone mineral density (BMD) was measured in 186 patients with biologics-treated RA. We compared the characteristics of those with BMD ≥70 % of young adult mean (YAM) and those with BMD <70 % of YAM, and undertook multivariable logistic regression analysis to identify risk factors for bone loss. Mean age and disease duration, the proportion of females, scores in the Modified Health Assessment Questionnaire and history of vertebral fracture were significantly greater in the BMD <70 % of YAM group, but body mass index (BMI) was significantly lower in the BMD <70 % of YAM group. There was no significant difference between the groups in terms of other biomarkers of RA activity, the proportion treated with methylprednisolone, or the duration or choice of biologics. The proportions of patients treated with anti-osteoporosis drugs and parathyroid hormone were significantly higher in the BMD <70 % of YAM group. In the multivariable analysis, advanced age, female, longer disease duration, history of past thoracic or lumbar vertebral fracture, higher Steinbrocker classification and lower BMI were significant factors for BMD <70 % of YAM. We identified risk factors for bone loss in patients with RA treated with biologics. Before suppression of disease activity by biologics, bone loss might already be advanced. We recommend that patients with RA who possess these risk factors be considered for earlier and more intense treatment to prevent bone loss, as well as addressing RA disease progression.
- 30 September 2015
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 16 (1) , 269
Open AccessRisk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
Osteoporosis is a complication of rheumatoid arthritis (RA). We identified risk factors for osteoporosis during treatment with biologics. Femoral neck bone mineral density (BMD) was measured in 186 patients with biologics-treated RA. We compared the characteristics of those with BMD ≥70 % of young adult mean (YAM) and those with BMD <70 % of YAM, and undertook multivariable logistic regression analysis to identify risk factors for bone loss. Mean age and disease duration, the proportion of females, scores in the Modified Health Assessment Questionnaire and history of vertebral fracture were significantly greater in the BMD <70 % of YAM group, but body mass index (BMI) was significantly lower in the BMD <70 % of YAM group. There was no significant difference between the groups in terms of other biomarkers of RA activity, the proportion treated with methylprednisolone, or the duration or choice of biologics. The proportions of patients treated with anti-osteoporosis drugs and parathyroid hormone were significantly higher in the BMD <70 % of YAM group. In the multivariable analysis, advanced age, female, longer disease duration, history of past thoracic or lumbar vertebral fracture, higher Steinbrocker classification and lower BMI were significant factors for BMD <70 % of YAM. We identified risk factors for bone loss in patients with RA treated with biologics. Before suppression of disease activity by biologics, bone loss might already be advanced. We recommend that patients with RA who possess these risk factors be considered for earlier and more intense treatment to prevent bone loss, as well as addressing RA disease progression.